Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.adaj.2016.08.016 | DOI Listing |
Oral Dis
January 2025
State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.
Objectives: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe complication of bisphosphonate therapy, with unclear mechanisms. This study investigates the regulatory impact of zoledronic acid (ZOL) on osteoclasts and microRNA (miRNA) expression.
Materials And Methods: Raw264.
J Maxillofac Oral Surg
December 2024
Dental Implants Research Center, Dental Research Institute, School of Dentistry, Isfahan University of Medical Sciences, Hezar Jerib Avenue, Isfahan, Iran.
Background: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) presents significant clinical challenges with uncertain treatment outcomes. Teriparatide, a fragment of human parathyroid hormone, shows potential in prevention strategies for BRONJ.
Objective: This study investigates the impact of a single local dose of teriparatide on BRONJ prevention in an animal model.
Cureus
October 2024
Department of Prosthodontics, Manav Rachna Dental College, Faridabad, IND.
The overview was carried out to evaluate the impact of antiresorptive drug (ARD) therapy in patients undergoing dental implant treatment who significantly experience medication-related osteonecrosis of the jaw (MRONJ) or not. A comprehensive electronic database search within the timeline of 2014-2024, restricted to the English language, was performed in database search engines like Google Scholar, Web of Science, PubMed, and Scopus. The articles were screened using the specific Medical Subject Headings (MeSH) terms and Boolean operators 'OR' and 'AND'.
View Article and Find Full Text PDFClin Transl Med
November 2024
Department of Oral and Maxillofacial Surgery, The Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing, China.
Background: Bisphosphonates (BPs) are the first-line treatment to stop bone resorption in diseases, including osteoporosis, Paget's disease, multiple myeloma and bone metastases of cancer. However, BPs-related osteonecrosis of the jaw (BRONJ), characterized by local inflammation and jawbone necrosis, is a severe intractable complication. The cumulative inflammatory burden often accompanies impaired lymphatic drainage, but its specific impact on BRONJ and the underlying mechanisms remain unclear.
View Article and Find Full Text PDFCureus
October 2024
Oral and Maxillofacial Surgery, Private Practice, New Delhi, IND.
Medication-related osteonecrosis of the jaw (MRONJ) refers to the condition where the maxillary or mandibular bone becomes exposed and necrotic as a result of bisphosphonate therapy. The number of patients on bisphosphonates is increasing and so are the MRONJ cases. Since the initial data were published in the early 2000s, research into MRONJ has expanded significantly to enhance the understanding of this emerging condition.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!